Lilly prices new clot-buster at 31% premium

Eli Lilly launched its new blood thinner in its first market today: the U.K. Effient/Efient (prasugrel) is priced 31 percent higher than its rival Plavix, the world's leading anticoagulant marketed by Bristol-Myers Squibb and Sanofi Aventis. Report